Hospital Kuala Lumpur & Rare Disease Patient Organizations Nationwide Celebrate Rare Disease Day 2025

March 01, 2025 02:30 PM GMT | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp
 Hospital Kuala Lumpur & Rare Disease Patient Organizations Nationwide Celebrate Rare Disease Day 2025
Image source: Kalkine Media

KUALA LUMPUR, Malaysia, March 1, 2025 /PRNewswire/ -- For the first time, Hospital Kuala Lumpur (HKL) is proudly hosting the annual Rare Disease Day 2025 celebration to raise awareness and advocate for individuals affected by rare diseases in Malaysia. This milestone event is organized by the Department of Genetics, Hospital Kuala Lumpur, in collaboration with Pharm-D Health Science, the main sponsor, alongside various patient advocacy groups.

With the theme "More Than You Can Imagine", this global initiative aims to highlight the challenges faced by rare disease patients, including delays in diagnosis, limited access to genetic testing, and the high cost of treatment.

Speaking at the event, Dato' Dr. Harikrishna a/l K. Ragavan Nair, Director of Hospital Kuala Lumpur, emphasized the need for stronger policies and diversified funding options to improve access to genetic testing and treatment for rare disease patients.

"Rare diseases impact more individuals than we realize – 1 in 17 people worldwide. This means that each of us likely knows someone living with a rare disease, whether they are a family member, a colleague, or a friend. Today's event is not just a celebration but a movement that brings together healthcare professionals, researchers, policymakers, patient advocacy groups, and industry leaders to work towards better diagnosis, treatment, and quality of life for these patients," said Dato' Dr. Harikrishna.

This year's Rare Disease Day celebration emphasizes the need for equity in healthcare, support, and opportunities for the rare disease community in Malaysia. With many Malaysians affected by rare diseases, ensuring fair access to timely diagnosis, treatment, and social inclusion is more crucial than ever.

Head of the Genetics Department Hospital Kuala Lumpur, Dr. Ngu Lock Hock, further underscored the importance of collective efforts in supporting rare disease patients. "Malaysia officially defined rare diseases in 2020 as life-threatening or chronically debilitating conditions affecting fewer than 1 in 4,000 individuals. Over 70% of rare diseases are genetic, and many cases involve children. At HKL's Genetics Department, we have provided consultations to over 10,000 families and conduct around 1,000 genetic tests annually.

These efforts are made possible through the strong support and commitment of the Ministry of Health, Hospital Kuala Lumpur, Hospital Tunku Azizah, as well as collaborations with various departments, NGOs, patient organizations, industry partners, and the private sector. Moving forward, strengthening these collaborations will be key to improving timely diagnosis and expanding access to treatment for rare disease patients," he shared.

As part of the initiative to improve rare disease awareness, the event also marked the launch of three new books tailored for patients and caregivers: "Buku Resipi Rendah Protein untuk Pesakit Inherited Metabolic Disorders (IMD)", produced through a collaboration between HKL's dietitians and the Genetics Department, with printing support from Pharm-D Health Science. "Pengembaraan Morquio A" and "Mia & Penjelajahan MPS 6", engaging comic-style books that are designed to help children with Morquio Syndrome and Mucopolysaccharidosis type 6 (MPS VI) to better understand their condition.

Pharm-D Health Science supported this event through its JARANG Program, a corporate social responsibility (CSR) initiative aimed to raise awareness, provide support, and empower individuals and families affected by rare diseases in Malaysia. Mr. Wong Chin Cheang, Managing Director of Pharm-D Health Science, expressed the company's commitment to bridging healthcare gaps in the rare disease community.

"Pharm-D Health Science believes in empowering the rare disease community through innovation and collaboration. Through the JARANG Program, we are dedicated to supporting awareness campaigns like today's event. Together, we can drive meaningful change and make a lasting impact on patients' lives," said Mr. Wong.

A highlight of the event was the mock cheque handover ceremony, where AGTC Genomics sponsored and Pharm-D Health Science supported the contribution of RM75,000 worth of whole exome sequencing (WES) tests for underprivileged patients. This funding will enable critical genetic testing, which is often a significant financial burden for affected families.

As the event concluded, Dr. Ngu called for continued collaboration to improve the lives of rare disease patients. "Together, we can make a difference – by listening, understanding, and taking action to bring hope to the rare disease community."

From the right: Mr. Wong Chin Cheang (Managing Director of Pharm-D Health Science) and Prof Leong Chee Onn (CEO of AGTC Genomics) presenting a Whole Exome Sequencing genomic tests sponsorship worth RM 75,000 to Dr. Ngu Lock Hock (Head of Department of Genetics, Hospital Kuala Lumpur) (Left), witnessed by Dato’ Dr. Harikrishna K. R Nair (Pengarah Hospital Kuala Lumpur) and Dr. Shamsul Anuar bin Kamarudin (Pengarah Hospital Tunku Azizah).
From the right: Mr. Wong Chin Cheang (Managing Director of Pharm-D Health Science) and Prof Leong Chee Onn (CEO of AGTC Genomics) presenting a Whole Exome Sequencing genomic tests sponsorship worth RM 75,000 to Dr. Ngu Lock Hock (Head of Department of Genetics, Hospital Kuala Lumpur) (Left), witnessed by Dato’ Dr. Harikrishna K. R Nair (Pengarah Hospital Kuala Lumpur) and Dr. Shamsul Anuar bin Kamarudin (Pengarah Hospital Tunku Azizah).

 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalized advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

AI on the Rise: A Look at Top AI Companies and Their Stocks

Recent Articles

Investing Tips

Previous Next